FDA approves Sandoz’s natalizumab biosimilar, likely putting a damper on Biogen’s Tysabri sales
On the back of Sandoz’s FDA approval for the first-ever natalizumab biosimilar, branded as Tyruko, Biogen now has a formidable multiple sclerosis market competitor for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
